Vera Therapeutics completes full enrollment in pivotal ORIGIN phase 3 trial for Atacicept in patients with IgA ...
Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced that it has completed full enrollment in the pivotal ORIGIN …